Drug Trial Radar · NCT05764590
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Feb 20, 2023
Primary completion
Aug 25, 2023
Study completion Sep 14, 2023
Sponsor
- Lead sponsor
- Alebund PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: * How much effect AP-306 has assessed by blood phosphorus lowering; * How safe and tolerable AP-306 is. Participants will receive either following treatments: * AP-306, and * Sevelamer carbonate.
Conditions
- Chronic Kidney Diseases
- Hyperphosphatemia
Interventions
AP-306Drug
A blood phosphorus lowering drug with a novel mechanism
Sevelamer CarbonateDrug
A phosphate binder
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of AP-306 assessed by serum phosphorus loweringTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.